grace capital decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 16.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,103 shares of the medical research company’s stock after selling 2,800 shares during the quarter. grace capital’s holdings in Amgen were worth $2,603,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Kwmg LLC purchased a new position in shares of Amgen during the second quarter worth about $108,000. Braun Bostich & Associates Inc. purchased a new position in shares of Amgen during the first quarter worth about $113,000. WealthTrust Fairport LLC purchased a new position in shares of Amgen during the first quarter worth about $121,000. Cornerstone Advisors Inc. grew its holdings in shares of Amgen by 76.5% during the first quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock worth $124,000 after buying an additional 316 shares during the last quarter. Finally, Gables Capital Management Inc. purchased a new position in shares of Amgen during the first quarter worth about $174,000. 77.20% of the stock is currently owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $195.71, for a total transaction of $298,457.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.19% of the stock is currently owned by company insiders.
Shares of AMGN opened at $200.58 on Monday. Amgen, Inc. has a twelve month low of $163.31 and a twelve month high of $204.42. The company has a market capitalization of $129.13 billion, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 1.94 and a beta of 1.39. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.52 by $0.31. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. During the same quarter in the previous year, the company earned $3.27 EPS. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. analysts expect that Amgen, Inc. will post 13.95 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 7th. Stockholders of record on Friday, August 17th were given a dividend of $1.32 per share. The ex-dividend date of this dividend was Thursday, August 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.63%. Amgen’s payout ratio is 41.97%.
A number of equities analysts recently issued reports on the company. Jefferies Financial Group set a $220.00 price target on Amgen and gave the stock a “buy” rating in a report on Wednesday, September 12th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a report on Monday, September 10th. Royal Bank of Canada reissued a “neutral” rating and set a $193.00 price target on shares of Amgen in a report on Monday, September 10th. Wells Fargo & Co reissued a “neutral” rating and set a $197.00 price target on shares of Amgen in a report on Wednesday, August 29th. Finally, Cann reissued a “buy” rating and set a $224.00 price target on shares of Amgen in a report on Monday, July 30th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $202.76.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: Stop Order
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.